Committed to improving patient outcomes
Building on more than 50 years of trailblazing liver treatment, our team of hepatologists and transplant surgeons are dedicated to patient-centered care. As the Stravitz-Sanyal Institute expands, more revolutionary treatment options will become available for patients with liver diseases.
Nonalcoholic steatohepatitis, or NASH, is a chronic form of fatty liver disease that is often the precursor to advanced liver disease and a leading cause for liver transplantation. Unrelated to alcohol abuse but closely linked to obesity and Type 2 diabetes, NASH generates a buildup of fat in the liver that damages cells and causes inflammation. For many patients, NASH can cause scarring, or fibrosis, which prevents the liver from functioning properly and can lead to cirrhosis. In severe cases, the condition can lead to liver cancer, liver failure or death.
Our research team is actively investigating new treatment methods for NASH. In 2019, a Phase III clinical trial was the first to demonstrate the safety and effectiveness of an oral medication to treat NASH. The drug therapy is pending approval from the U.S. Food and Drug Administration. In 2021, Arun Sanyal, M.D., and other researchers published findings from a study to help close the gaps in knowledge and awareness of NASH and nonalcoholic fatty liver disease, or NAFLD. With an improved understanding of these diseases, there is a better chance of developing viable treatment options for patients.
Our dedicated physicians and nurses treat patients with more than 100 conditions and diseases known to affect the liver, including viral hepatitis, nonalcoholic fatty liver disease and hepatocellular carcinoma.
Providing compassionate care with survival rates at or above the national average, Hume-Lee performs liver transplants for the treatment of diseases such as fatty liver disease, acute liver failure and primary biliary cirrhosis.